Podcasts about beta blockers

Jenn & Jess talk about what went on behind the scenes of this week's Met Gala. Plus: caveman skin, TikTok's newest trend (if you can call it that); what all the brides want in their hair this wedding season; new research on glutathione; a life-size scratch-and-sniff marketing campaign; Westman Atelier Bronzing Drops vs. Saie Cream-Balm Bronzer; and some fun Raise A Wands!Episode recap: fatmascara.com/blog/ep-577Products mentioned in this episode: shopmy.us/collections/1635167Sponsor links & discount codes: fatmascara.com/sponsorsPrivate Facebook Group: Fat Mascara Raising a WandTikTok & Instagram: @fatmascara, @jenn_edit, @jessicamatlin + contributors @garrettmunce, @missjuleeSubmit a "Raise A Wand" product recommendation: text us or leave a voicemail at 646-481-8182 or email info@fatmascara.com Become a member at https://plus.acast.com/s/fatmascara. Hosted on Acast. See acast.com/privacy for more information.

Beta blocking medications attach to Beta receptors to inhibit or “block” the effects of epinephrine (adrenaline)and norepinephrine in the body.The primary locations of Beta I, II, and III receptors.Effects of epinephrine & norepinephrine's stimulation of beta receptors on the heart.Beta blockers effects on the heart.When we should consider the use of beta blockers in the Acute Coronary Syndrome (ACS)and Tachycardia algorithms.Contraindications to the use of beta blocker medications.More detailed information about beta blocker's mechanism of action and specific instances for their use can be found on the Pod Resource page at PassACLS.com. Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/Free Prescription Discount Card - Download your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vip/savePass ACLS Web Site - Episode archives & other ACLS-related podcasts: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

Coaches Justin, William, and Amanda do coaching! Check them out here!   In this episode of the Bacon Bibles and Barbells podcast, Coaches Justin, Bill, and Amanda delve into the topic of beta blockers, discussing their mechanisms, uses, and implications for both health and athletic performance. They explore the pros and cons of beta blockers, particularly in relation to anxiety management and blood pressure control, while also considering the safety risks for athletes. The conversation highlights the importance of lifestyle interventions and compares beta blockers with SSRIs, emphasizing the need for careful consideration before using any medication. The episode concludes with recommendations for managing anxiety and improving overall health through lifestyle changes.   Some key takeaways Beta blockers are one of the oldest blood pressure medications. They work by blocking beta receptors that respond to adrenaline. Beta blockers can reduce heart rate and blood pressure. They are commonly used for anxiety management in certain situations. Athletes may experience decreased performance on beta blockers. Safety risks include potential fainting and reduced circulation. Lifestyle interventions are often more effective than medication. SSRIs can have significant side effects compared to beta blockers. Breath work and other techniques can help manage anxiety. Consulting a doctor about medication options is crucial for athletes.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Beta-Blockers After PCI for Stable Coronary Artery Disease and Preserved Left Ventricular Ejection Fraction

Welcome back to this week's Friday Review where we'll be covering the very best of the week including reviewing these topics:     Copper Dry Brush (product review) Fasting Cancer (book review) Depression & Beta-Blockers (research) Zinc & Pneumonia (research)     For all the details tune into today's Cabral Concept 3304 – Enjoy the show and let me know what you thought!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3304 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

This week the lassies discuss the wee toothy fish, Beta Blockers and Blake LivelyLike, share, and subscribe to @materialgirlcomedyMake sure to check out:Material Girl Podcast https://linktr.ee/materialgirlcomedyMaterial Girl Live shows https://linktr.ee/materialgirlcomedyMaterial Girl Newsletter https://substack.com/@materialgirlcomedyFollow Susan Riddell & Amanda Dwyer & Material Girl on socials:@susanriddellcomedian https://linktr.ee/susrid@amandadwyerrlolYou can follow Material Girl on Instagram and TikTok for clips, news and more! Leave a 5 star review!Email us your questions: materialgirlthepodcast@gmail.com#podcast #comedy #podcastclips #funny #standupcomedy #jokes #fyp #womenincomedy #materialgirlcomedy #susanriddell #amandadwyer Hosted on Acast. See acast.com/privacy for more information.

Beta blocking medications attach to Beta receptors to inhibit or “block” the effects of epinephrine (adrenaline)and norepinephrine in the body. The primary locations of Beta I, II, and III receptors. Effects of epinephrine & norepinephrine's stimulation of beta receptors on the heart. Beta blockers effects on the heart. When we should consider the use of beta blockers in the Acute Coronary Syndrome (ACS)and Tachycardia algorithms. Contraindications to the use of beta blocker medications. More detailed information about beta blocker's mechanism of action and specific instances for their use can be found on the Pod Resource page at PassACLS.com. Connect with me:Website: https://passacls.com@Pass-ACLS-Podcast on LinkedInGive Back & Help Others: Your support helps cover the monthly cost of software and podcast & website hosting. Donations at Buy Me a Coffee at https://buymeacoffee.com/paultaylor are appreciated and will help ensure others can benefit from these tips as well.Good luck with your ACLS class!Helpful Listener Links:Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/*FREE to anyone in the U.S. Save $$ on prescription medications for you and your pets with National Drug Card - https://nationaldrugcard.com/ndc3506 *Indicates affiliate links. I may get paid a small commission if you purchase products or memberships using my link. It doesn't affect the price you pay.

Erectile Dysfunction affects 20-30 million American men and is likely under-reported. But 85% of cases are due to underlying health issues like Cardiovascular Disease. In this episode, you'll learn:—The difference between Male Impotence and Erectile Dysfunction.—How pharmaceuticals (like anti-Cholesterol medicines, Beta Blockers, and anti-depressants) are big contributors to E.D.—The astonishing statistics about declining Testosterone levels in military men since World War II. (And how these low levels are even being seen in young men who are still teenagers.)—The role Atherosclerosis and Diabetes play in E.D. And how Atherosclerosis is the #1 contributor to E.D.—Why it is "very rare" for men over 50 to have E.D. due to psychological and not physical causes. And how your libido is a key indicator for your overall health.—The "Hand Test" Dr. Prather says you can use to gauge the health of a man's erection. —Why alcohol has a negative effect on male performance and can actually shrink the testicles. And how smoking even TWO cigarettes can cause E.D.—The dangers of marijuana use for male sexual performance, including issues of infertility. And why Dr. Prather says it is "really difficult" to get Testosterone levels back up to normal levels in marijuana users.—How pornography is actually destroying male sexual performance, not enhancing it. —Why Dr. Prather says your sexual life is linked to your nutrition and "the better your nutrition, the better your virility". And the natural supplements that help with male sexual performance.http://www.TheVoiceOfHealthRadio.com

Drs Harrington and Gibson review their picks for the top cardiology trials of 2024 and look ahead to 2025, particularly what health topics may be prioritized by the new administration. This podcast is intended for healthcare professionals only. To read a transcript or to comment https://www.medscape.com/author/bob-harrington Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction (REDUCE AMI) https://www.nejm.org/doi/abs/10.1056/NEJMoa2401479 Intensive Blood-Pressure Control in Patients with Type 2 Diabetes (BPROAD) https://doi.org/10.1056/nejmoa2412006 Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis EARLY TAVR https://www.nejm.org/doi/full/10.1056/NEJMoa2405880 Asundexian versus Apixaban in Patients with Atrial Fibrillation (OCEANIC-AF) https://doi.org/10.1056/NEJMoa2407105 In the Wake of OCEANIC-AF, Is Equipoise Regarding Factor XI Inhibition Still Afloat? https://www.jacc.org/doi/10.1016/j.jacc.2024.10.105 Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial https://doi.org/10.1016/S0140-6736(24)00413-6 Preventive Coronary Stents: Not There Yet https://www.medscape.com/viewarticle/preventive-coronary-stents-not-there-yet-2024a10006yr Speech by Commissioner Robert M. Califf to the House of Medicine June 16, 2023 https://www.fda.gov/news-events/speeches-fda-officials/speech-commissioner-robert-m-califf-house-medicine-06162023 Evolution of Single-Lead ECG for STEMI Detection Using a Deep Learning Approach https://doi.org/10.1016/j.ijcard.2021.11.039 From ST-Segment Elevation MI to Occlusion MI: The New Paradigm Shift in Acute Myocardial Infarction https://doi.org/10.1016/j.jacadv.2024.101314 You may also like: Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

Doctors fleeing Medicare—leaving patients stranded; CEO murder heightens scrutiny of United Healthcare's Medicare Advantage coding shenanigans; Can blood pressure spikes cause strokes? Does a calcium score of 20 call for a statin Rx? Treatments for postural orthostatic tachycardia syndrome (POTS); New “improved” tea bags release millions of plastic microparticles; The surprising trigger of a bout of hives. 

Qui dit fin d'année dit Gala des grands crus et des piquettes du Pharmascope! Ne manquez pas cette 8e édition du Gala au velours des plus sérieux, le grand retour de Sébastien, des effets sonores entraînants, l'inclusion de nouvelles catégories exotiques… ** Veuillez noter que cet épisode ne rencontre pas les critères d'admissibilité pour l'octroi d'unités de formation continue ou de crédits Mainpro+** Ressources pertinentes en lien avec l'épisode La catégorie « L'éditorial de l'année »van Dijk SHB, Bui M, Eijkelboom AH. Living happily ever after? The hidden health risks of Disney princesses. BMJ. 2024;387:q2497. La catégorie « Nouvelles études de vieilles affaires pour de vieilles maladies »Kingsbury SR, Tharmanathan P, Keding A, et al. Pain Reduction With Oral Methotrexate in Knee Osteoarthritis : A Randomized, Placebo-Controlled Clinical Trial. Ann Intern Med. 2024;177(9):1145-1156. Wang Y, Jones G, Keen HI, et al. Methotrexate to treat hand osteoarthritis with synovitis (METHODS): an Australian, multisite, parallel-group, double-blind, randomised, placebo-controlled trial. Lancet. 2023;402(10414):1764-1772. La catégorie « Patente à gosse incroyable »Bartholdy C, Døssing A, Stisen ZR, et al. Effect of heated mittens on physical hand function in people with hand osteoarthritis: randomised controlled trial. BMJ. 2024;387:e078222. La catégorie « Je pleure tellement je ris »Li J, Liao Y, Zhang SY, et al. Effect of laughter exercise versus 0.1% sodium hyaluronic acid on ocular surface discomfort in dry eye disease: non-inferiority randomised controlled trial. BMJ. 2024;386:e080474. La catégorie « Alimentaire »Hakam N, Guzman Fuentes JL, Nabavizadeh B, et al. Outcomes in Randomized Clinical Trials Testing Changes in Daily Water Intake: A Systematic Review. JAMA Netw Open. 2024;7(11):e2447621. Hodder RK, O'Brien KM, Wyse RJ, et al. Interventions for increasing fruit and vegetable consumption in children aged five years and under. Cochrane Database Syst Rev. 2024;9(9):CD008552. La catégorie « On n'est plus capable! »Duarte Romero B, Waterhouse M, Baxter C, et al. The effect of three years of vitamin D supplementation on erectile dysfunction: Results from the randomized placebo-controlled D-Health Trial. Clin Nutr ESPEN. 2024;60:109-115. La catégorie « L'étude ayant pris le plus de temps à être publiée »Hammond J, Fountaine RJ, Yunis C, et al. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. N Engl J Med. 2024;390(13):1186-1195. La catégorie « Visuospatial »R Patel V, Liu M, Worsham CM, Jena AB. Alzheimer's disease mortality among taxi and ambulance drivers: population based cross sectional study. BMJ. 2024;387:e082194. Published 2024 Dec 17. La catégorie « Hommage »Yndigegn T, Lindahl B, Mars K, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;390(15):1372-1381. Silvain J, Cayla G, Ferrari E, et al. Beta-Blocker Interruption or Continuation after Myocardial Infarction. N Engl J Med. 2024;391(14):1277-1286.

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Beta-Blockers⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Pharmacology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Weird head tapping routines, toy lobsters on stage - Part 2 of Stage Fright uncovers the strange and diverse pre-concert routines some musicians go through, and what happens if you freeze in the middle of a performance. Fight or flight, to leave the stage or not to leave the stage, that is the question. And then the taboo topic of Beta Blockers enters the conversation... Host and MCO violist Yannick Dondelinger brings to a close this double episode of frank, funny and intimate discussion with MCO musicians around the effects, the origins, and some controversial solutions to having stage fright…. For a full transcript of the episode, please visit our website. 

This week Mark, Kate, Gary and Henry talk about the comparative effectiveness of migraine medications, strategies for adults with plantar fascia pain, whether to continue beta-blocker use after acute MI, and the outcomes of 5-alpha reductase inhibitor use prior to prostate cancer diagnosis. Links Migraine: https://www.bmj.com/content/386/bmj-2024-080107 Plantar fasciitis: https://pubmed.ncbi.nlm.nih.gov/38904119/  and https://pubmed.ncbi.nlm.nih.gov/16801514/ Beta-blockers post MI: https://pubmed.ncbi.nlm.nih.gov/39213187/ Prostate cancer: https://pubmed.ncbi.nlm.nih.gov/39190306/

Beta blocking medications attach to Beta receptors to inhibit or “block” the effects of epinephrine (adrenaline)and norepinephrine in the body. The primary locations of Beta I, II, and III receptors. Effects of epinephrine & norepinephrine's stimulation of beta receptors on the heart. Beta blockers effects on the heart. When we should consider the use of beta blockers in the Acute Coronary Syndrome (ACS)and Tachycardia algorithms. Contraindications to the use of beta blocker medications. More detailed information about beta blocker's mechanism of action and specific instances for their use can be found on the Pod Resource page at PassACLS.com. Connect with me:Website: https://passacls.com@Pass-ACLS-Podcast on LinkedInGive Back & Help Others: Your support helps cover the monthly cost of software and podcast & website hosting so that others can benefit from these ACLS tips as well. Donations via Buy Me a Coffee at https://buymeacoffee.com/paultaylor are appreciated.Good luck with your ACLS class!

From childhood trauma, to professional bow shake, to the elephant in the room - Beta Blockers. Some times you swallow the stage, and sometimes the stage swallows you… Stage fright is something we can all relate to, wether presenting a speech, teaching class, or chairing a meeting. This is especially true for the musicians of the Mahler Chamber Orchestra, who are out there on the worlds concert stages in front of thousands of people, every week, every year. Join host and violist Yannick Dondelinger for a double episode of frank, funny and intimate discussion with MCO musicians around the effects, the origins, and some controversial solutions to having stage fright. For a full transcript of the episode, please visit our website. 

Taylor Gullickson, PharmD educates on the use of beta-blockers in portal hypertension   For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes.  You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on X @MayoMedE 

In 2024 Nate Byrne went from presenting the weather to making the news when he acknowledged live on air that he was experiencing a panic attack. Keeping cool under pressure is a skill Nate developed in his first career as a Naval Officer, and perhaps also from his days as a go-go dancer in a Perth nightclub.

It's time for our semiannual mental health episode. Special shoutout to the anxious gigglers and Simone Biles.get tickets to live shows heresign up for our newsletter herepre-order our book here Hosted on Acast. See acast.com/privacy for more information.

It's been a long time, but we are back!Apologies on the audio quality from Dr. Jenkins. Apparently he was recording from inside a cardboard box.Today we talk about important, practice changing studies in internal medicine from the last several months. What's the best anticoagulant in patients with cirrhosis and atrial fibrillation? Why do doctors use so much unfractionated heparin for acute PE? Should we still be using beta blockers in patients with acute MI? Does finerenone improve outcomes in HFpEF? Is continuous infusion of antibiotics better than intermittent? And will the cefepime vs piperacillin-tazobactam battle ever end?Apixaban, Rivaroxaban and Warfarin in Cirrhosis for AFAnticoagulation Trends for Acute PEBeta Blockers for Acute MI with Normal EF Finerenone for HFpEF FINEARTS-HFContinuous vs Intermittent Infusion of Beta-Lactams BLING IIIProlonged vs Intermittent Infusions of Beta-Lactams Meta-analysisPiperacillin-Tazobactam vs Cefepime for SepsisRecurrent SBP in Patients on Secondary Prophylaxis

Beta blocking medications attach to Beta receptors to inhibit or “block” the effects of epinephrine (adrenaline)and norepinephrine in the body. The primary locations of Beta I, II, and III receptors.Effects of epinephrine & norepinephrine's stimulation of beta receptors on the heart.Beta blockers effects on the heart.When we should consider the use of beta blockers in the Acute Coronary Syndrome (ACS)and Tachycardia algorithms. Contraindications to the use of beta blocker medications.More detailed information about beta blocker's mechanism of action and specific instances for their use can be found on the Pod Resource page at PassACLS.com.Connect with me:Website: https://passacls.com@Pass-ACLS-Podcast on LinkedInGive Back & Help Others: Your support helps cover the monthly cost of software and podcast & website hosting so that others can benefit from these ACLS tips as well. Donations made via Buy Me a Coffee at https://buymeacoffee.com/paultaylor are appreciated.Make a difference in the fight against breast cancer by donating to my Men Wear Pink fundraiser for the American Cancer Society (ACS) at http://main.acsevents.org/goto/paultaylor Every dollar helps in the battle with breast cancer.Good luck with your ACLS class!

Learn about a study in NEJM which found no significant benefits from discontinuing beta-blocker therapy in MI patients, gut microbiota's potential influence on hematologic cancers and, data from ESC Congress 2024 suggesting that catching up on sleep during weekends may reduce heart disease risk by up to 20%.

Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.

With good healthcare becoming harder to find, and afford, more and more people are turning to Telehealth medicine to get their prescriptions. Generally this type of online Doc has been associated with the trendier drugs with sexy promises. From “boner pills” to weight loss drugs, Telehealth has become the easy and cheap way to get these “tabloid drugs.” Now, there's more talk about beta blockers and arguably abusing them because they are being used for the wrong reasons. And prescribed by doctors who don't know the patient or their medical history. If you are thinking about taking beta blockers before a big date, an important pitch meeting, or because you think it's a daily solution for anxiety, this Hot Take is a must listen!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Editor's Summary by Anne Cappola, MD, ScM, Associate Editor of JAMA, the Journal of the American Medical Association, for the August 13, 2024, issue.

Join us for a conversation with John C. Hagan III, an ophthalmologist, as we delve into the innovative use of beta-blockers for treating acute migraines. Discover the journey behind the discovery of Timolol's efficacy in migraine relief and the challenges faced in securing pharmaceutical support. Gain insights into the potential future of beta-blocker nasal sprays and the importance of pursuing innovative, low-cost treatments in the medical field. John C. Hagan III is an ophthalmologist. He discusses the KevinMD article, "Big pharma ignores low-cost migraine solution." Our presenting sponsor is Nuance, a Microsoft company. Do you spend more time on administrative tasks like clinical documentation than you do with patients? You're not alone. Clinicians report spending up to two hours on administrative tasks for each hour of care provided. Nuance, a Microsoft company, is committed to helping clinicians restore the balance with Dragon Ambient eXperience – or DAX for short. DAX is an AI-powered, voice-enabled solution that helps physicians cut documentation time in half. DAX Copilot combines proven conversational and ambient AI with the most advanced generative AI in a mobile application that integrates directly with your existing workflows. DAX Copilot can be easily enabled within the workflow of the Dragon Medical application to bring the power of ambient technology to more clinicians faster while leveraging the proven and powerful capabilities used by over 550,000 physicians. Explore DAX Copilot today. Visit https://nuance.com/daxinaction to see a 12-minute DAX Copilot demo. Discover clinical documentation that writes itself and reclaim your work-life balance. VISIT SPONSOR → https://nuance.com/daxinaction SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus

Beta blocking medications attach to Beta receptors to inhibit or “block” the effects of epinephrine (adrenaline)and norepinephrine in the body. The primary locations of Beta I, II, and III receptors. Effects of epinephrine & norepinephrine's stimulation of beta receptors on the heart.Beta blockers effects on the heart. When we should consider the use of beta blockers in the Acute Coronary Syndrome (ACS) and Tachycardia algorithms. Contraindications to the use of beta blocker medications. More detailed information about beta blocker's mechanism of action and specific instances for their use can be found on the Pod Resource page at PassACLS.com. Connect with me:Website: https://passacls.com@PassACLS on X (formally known as Twitter)@Pass-ACLS-Podcast on LinkedInGive back & help others. Your support will help cover the monthly cost of software and podcast & website hosting. Donations made via Buy Me a Coffee at https://buymeacoffee.com/paultaylor are appreciated.Good luck with your ACLS class!

N Engl J Med 2024;390:1372-1381Background: Beta-blockers are prescribed to the majority of patients with acute myocardial infarction. The bulk of evidence supporting this practice comes from trials published in the 1980s - BHAT and ISIS-I. Since the publication of these seminal trials, the care of patients with acute myocardial infarction has significantly changed with improvement in antiplatelet therapy, the addition of high-intensity statins and renin–angiotensin–aldosterone system antagonists in addition to early revascularization for STEMI patients. Furthermore, myocardial injury is now detected based on high-sensitivity troponin assays which can detect smaller myocardial infarctions. Therefore, there is a lack of evidence whether beta-blockers provide benefit for patients with acute myocardial infarction in the current era.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.The Randomized Evaluation of Decreased Usage of Beta-Blockers after Acute Myocardial Infarction (REDUCE-AMI) trial sought to assess whether long-term oral beta-blocker treatment improves outcomes in patients with acute myocardial infarction and preserved left ventricular ejection fraction.Patients: Eligible patients were adults, 1 to 7 days after myocardial infarction who underwent coronary angiography and echocardiography. Patients were required to have obstructive coronary artery disease on coronary angiography defined as stenosis of ≥50%, a fractional flow reserve of ≤0.80, or an instantaneous wave-free ratio of ≤0.89 at any time point before randomization. Left ventricular Ejection fraction on echocardiogram had to be ≥50%. Patients were excluded if they had contraindications to beta-blockers or if the treating physician determined that treatment with beta-blockers is indicated for other conditions.Baseline characteristics: The trial randomized 2,508 patients to the beta-blockers group and 2,512 patients to the control group. The average age of patients was 65 years with 78% being men. About 20% were current smokers, 46% had hypertension, 14% had diabetes, 7% had prior myocardial infarction and < 1% had prior heart failure.The index event was STEMI in 35% of the patients. About 96% underwent percutaneous coronary intervention. The median heart rate was 74 bpm and the median systolic blood pressure was 151 mm Hg.Medications at discharge included aspirin in 97% of the patients, P2Y12 inhibitors in 96%, ACEi or ARBs in 80% and statins in 99%.Procedures: Patients were randomized 1:1 to receive metoprolol succinate (first choice), bisoprolol (second choice) or no beta-blockers. The target doses were at least 100 mg daily for metoprolol succinate and at least 5 mg daily for bisoprolol. Patients in the control group were discouraged from using beta-blockers; they did not receive placebo. If a patient was on beta-blocker therapy at the time of enrollment and was randomly assigned to the no–beta-blocker group, the beta-blocker had to tapered off over a period of 2 to 4 weeks.Endpoints: The primary end point was a composite of death from any cause or new myocardial infarction. Secondary end points were death from any cause, death from cardiovascular causes, myocardial infarction, hospitalization for atrial fibrillation as primary diagnosis, and heart failure hospitalization. There were three safety endpoints: 1- Hospitalization for bradycardia, second- or third-degree atrioventricular block, hypotension, syncope, or implantation of a pacemaker, 2- hospitalization for asthma or chronic obstructive pulmonary disease as a primary diagnosis and 3- hospitalization for stroke.Data on clinical end points were not centrally adjudicated but rather obtained from the SWEDEHEART registry and the Swedish Population Registry.Statistical analysis was performed based on the intention-to-treat principle. Before trial initiation, the estimated event rate in the control group was 7.2%/ year and at least 16.7% lower event rate in the beta-blocker group was considered clinically meaningful. During the trial, the actual event rate in control group was 3%/ year. Given this event rate, a 25% lower event rate in the beta-blocker group was considered clinically meaningful. A total of 379 primary end point events were needed in order to have 80% power at a two-sided alpha of 0.05, to detect the 25% lower event rate with beta-blockers. The estimated number of patients needed was about 5,000.Results: Among the patients who attended the SWEDEHEART registry, 1500/1831 (81.9%) of the beta-blocker group were still taking beta-blockers after 11 to 13 months; compared to 269/ 1886 (14.3%) in the no beta-blocker group.After a median follow up time of 3.5 years, beta-blockers did not the reduce the composite primary endpoint compared to no beta-blockers (7.9% vs 8.3%, HR: 0.96; 95% CI, 0.79 - 1.16; p= 0.64). There were no significant differences in death from any cause (3.9% vs 4.1%), death from cardiovascular causes (1.5% vs 1.3%), myocardial infarction (4.5% vs 4.7%), hospitalization for atrial fibrillation (1.1% vs 1.4%) or hospitalization for heart failure (0.8% vs 0.9%).Safety endpoints were also not significantly different between both groups; 3.4% vs 3.2% for the bradyarrhythmia, syncope or hypotension endpoint, 0.6% in both groups for the hospitalization for asthma or COPD endpoint and 1.4% vs 1.8% for hospitalization for stroke.There were no significant subgroup interactions.Conclusion: In patients with acute myocardial infarction who underwent coronary angiography and had preserved left ventricular systolic function, treatment with beta-blockers did not improve outcomes over a 3.5-year follow-up. Events were infrequent in the trial; 1.4% for cardiovascular death, 4.6% for recurrent myocardial infarction and 0.8% for hospitalization for heart failure. The low event rate in this population in the current era makes it difficult to demonstrate additional benefit with more therapies.The open-label design of the study may have introduced performance bias; however, this bias is expected to favor beta-blockers given the superiority design of the study. Another limitation, as noted by the authors, is that outcomes were obtained from the SWEDEHEART registry and the Swedish Population Registry and were not centrally adjudicated. However, this is expected to affect both groups equally.We believe the divergent results between this trial and older beta-blocker trials in myocardial infarction patients such as BHAT and ISIS-1 which were published in the 1980s, is due to the significant improvement in the management of acute myocardial infarction over time including improved medical therapy in addition to early revascularization for STEMI patients. This improved patient care has led to significantly lower mortality rates over time. For instance, all-cause death in the control arm of REDUCE-AMI is significantly lower than that of BHAT and ISIS-1, at 4.1% vs 9.8% and 11.9%, respectively. This is despite REDUCE-AMI having a longer follow-up period of 3.5 years compared to 2.1 years and 1 year in the earlier trials.In conclusion, this study does not provide evidence that beta-blockers improve outcomes for patients with acute myocardial infarction and preserved ejection fraction in the contemporary era.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

It's cardiovascular day at Primary Care Update as Kate, Mark and Henry discuss bleeding risk with diltiazem in treatment for atrial fibrillation, whether alteplase improves outcomes in patients with minor ischemic stroke, and whether to continue beta-blockers long-term after acute MI with preserved ejection fraction.

We have merch! Shop our collection here! https://puddlespodcast.myspreadshop.com/ Welcome to Puddles. Andrew and Brenna joke about everything, mostly their own relationship. In this episode we cover being hot and young, our first 3 hours in Florida, our parents meeting for the first time, Brenna meeting Rusty, Trisha Paytas's new baby, new vocabulary words, White City, FL, and how cocaine is the fix for every disease. Want to hear more? Subscribe to our Patreon for extra bonus content every week! patreon.com/thepuddlespodcast Leave us a voicemail Send us questions: puddleboyandpuddlegirl@gmail.com Don't forget to subscribe to our Patreon for extra bonus content every week! Chapters 00:00 - We're back 04:35 - Hot and Young 05:45 - Empirical evidence 09:20 - Dermatologists 10:30 - I Newsom Gavin in my day 14:00 - Beta blockers 18:00 - White City, Florida 19:30 - Father and daughter 21:00 - Brenna said yes to the dress 23:00 - Mango vs. Mirror 25:30 - a real puddle 28:00 - The wedding venue 31:00 - $8,000 Charcoochie boards 35:00 - Nachos for 80 people 39:00 - Snews 42:00 - Slander 47:30 - Infant soft launch 51:00 - Patreon! 52:00 - Floppy Firemen 54:00 - Andrew's Dad joins the Bachelor party SUBSCRIBE! Puddles Youtube Feed Puddles Podcast iTunes Audio Feed Puddles Podcast Spotify Audio Feed FOLLOW US: Puddles - instagram.com/puddlespodcast Andrew - instagram.com/andrewtcollin Brenna - instagram.com/brennaalexiss Melanie - instagram.com/melaniemeisner Theme song performed by: Ed Glaser Ending song written by: Andrew Collin Visuals and Graphics by: Melanie Meisner Produced by: Melanie Meisner

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Long-term beta blockers after myocardial infarction Pros and Cons of the microaxial pump in cardiogenic shock Snapshots Host: Perry Elliott Guests: Stephan Achenbach, Carlos Aguiar, Michael Boehm, Lene Holmvang Want to watch that episode? Go to: https://esc365.escardio.org/event/1151   Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Michael Boehm, Lene Holmvang and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

Long-term Beta-blocker Treatment After Acute Myocardial Infarction And Preserved Left Ventricular Ejection Fraction - The REDUCE-AMI Trial

Welcome back Rounds Table Listeners!We are back today with our Classic Rapid Fire Podcast!This week, Drs. Mike Fralick and Emily Hughes discuss two recent papers exploring the role of beta blockers after myocardial infarction when there is preserved ejection fraction and the utility of Paxlovid in vaccinated versus unvaccinated adult outpatients with symptomatic COVID-19. Two papers, here we go!Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with COVID-19 (0:00 – 14:02). Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction (14:02 – 27:24).And for the Good Stuff: A 65-Year-Old Woman with an Incorrect Operation on the Left Hand (27:24 – 31:04).Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old manQuestions? Comments? Feedback? We'd love to hear from you! @roundstable

IDM eases into this ep with a new edition of SOTJS before trying out a new bit.

The sixthirty podcast is back! Hosts Lydia & Jamie sit down to discuss the popular conspiracy the Mandela effect as well as why millennials and gen z are taking beta blockers. Enjoy the episode and thanks for listening! ***DON'T FORGET TO RATE US ON SPOTIFY & ITUNES*** Email: Sixthirtypodcast@gmail.com Facebook: @sixthirtypodcast Instagram: @sixthirty_network Tik Tok: @sixthirtypodcast Artlist.IO License #363835

ACC Recap #1: DanGer Shock (plus a sobering JAMA research letter on Impella use), REDUCE-AMI, PREVENT, and EMPACT-MI are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. DanGer-Shock Trial Impella CP Improves Survival in STEMI, Cardiogenic Shock https://www.medscape.com/viewarticle/impella-cp-improves-survival-stemi-cardiogenic-shock-2024a10006kz Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key https://www.medscape.com/viewarticle/1000659 Published DanGer Shock Study  https://www.nejm.org/doi/full/10.1056/NEJMoa2312572 JAMA Research letter https://jamanetwork.com/journals/jama/article-abstract/2817457 II. REDUCE-AMI Trial New Data Question Beta-Blockers Post-MI With Preserved EF https://www.medscape.com/viewarticle/new-data-question-beta-blockers-post-mi-preserved-ef-2024a10006y8 Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI https://www.medscape.com/viewarticle/1000663 REDUCE-AMI paper https://www.nejm.org/doi/full/10.1056/NEJMoa2401479 Meta-analysis: Beta Blockers for MI https://doi.org/10.1016/j.amjmed.2014.05.032 III. PREVENT Trial Preventive PCI for Vulnerable Plaques Reduces Cardiac Events https://www.medscape.com/viewarticle/preventive-pci-vulnerable-plaques-reduces-cardiac-events-2024a10006tc Preventive Coronary Stents: Not There Yet https://www.medscape.com/viewarticle/preventive-coronary-stents-not-there-yet-2024a10006yr PREVENT https://doi.org/10.1016/S0140-6736(24)00413-6 IV. EMPACT MI trial of Empagliflozin in the Post-MI setting Empagliflozin Fails to Reduce Events After Acute MI https://www.medscape.com/viewarticle/empagliflozin-fails-reduce-events-after-acute-mi-2024a10006kn EMPACT-MI: Another SGLT2 Inhibitor Miss in Post-MI Care  https://www.medscape.com/viewarticle/1000684 EMPACT MI https://www.nejm.org/doi/10.1056/NEJMoa2314051 DAPA MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286 PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508 Kaul thread https://x.com/kaulcsmc/status/1776611935842165029 Kaul paper https://www.ahajournals.org/doi/full/10.1161/circulationaha.116.022537 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Show notes at pharmacyjoe.com/episode904. In this episode, I’ll discuss whether patients taking beta-blockers require increased doses of epinephrine for anaphylaxis. The post 904: Do Patients Taking Beta-Blockers Require Increased Doses of Epinephrine for Anaphylaxis? appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode904. In this episode, I’ll discuss whether patients taking beta-blockers require increased doses of epinephrine for anaphylaxis. The post 904: Do Patients Taking Beta-Blockers Require Increased Doses of Epinephrine for Anaphylaxis? appeared first on Pharmacy Joe.

Beta blocking medications attach to Beta receptors to inhibit or “block” the effects of epinephrine (adrenaline)and norepinephrine in the body. The primary locations of Beta I, II, and III receptors. Effects of epinephrine & norepinephrine's stimulation of beta receptors on the heart. Beta blockers effects on the heart. When we should consider the use of beta blockers in the Acute Coronary Syndrome (ACS)and Tachycardia algorithms. Contraindications to the use of beta blocker medications. More detailed information about beta blocker's mechanism of action and specific instances for use can be found on the Pod Resource page at PassACLS.com.Connect with me:Website: https://passacls.com@PassACLS on X (formally known as Twitter)@Pass-ACLS-Podcast on LinkedInGive back - buy Paul a bubble tea hereGood luck with your ACLS class!

Dr. Dallen Mills from Peak View Anesthesia joins us once again to cast a wide net over the topic of anesthesia as we discuss beta blockers, ketamine, kidney failure, and a whole lot more! The last time he was here, Dr. Mills walked us through the ins and outs of Precedex. Today, he answers some follow-up questions by explaining how long you can use a Precedex solution after it's been diluted. Our guest goes on to describe his treatment plan for post-surgery combatant patients, his thoughts on using beta blockers with ketamine, how he uses nitrous oxide as an adjunct to sedation, and how he approaches sedating patients who have kidney complications. To end, Dr. Mills thoroughly examines everything related to taking medication before surgery. Tune in for all this and more!Key Points From This Episode:Dr. Dallen Mills explains the shelf life of a diluted Precedex solution. His go-to treatment for patients who wake up agitated from surgery. What he thinks about routinely using beta blockers with ketamine. How he deals with increased secretions of ketamine. The way Dr. Mills uses nitrous oxide in his daily operations. His protocol for treating patients with kidney failures and those on dialysis. Everything you need to know about taking medication prior to sedation. Links Mentioned in Today's Episode:Dr. Dallen Mill on LinkedIn — https://www.linkedin.com/in/dallen-mill-055338/ Peak View Anesthesia — https://www.pvanesthesia.com/  ‘The Pros and Cons of Precedex and Remifentanil, Plus a Dive into an Innovative Non-Pharmaceutical Approach (with Dr. Dallen Mill, MD Anesthesiologist)' — https://www.buzzsprout.com/1404670/14398433-the-pros-and-cons-of-precedex-and-remifentanil-plus-a-dive-into-an-innovative-non-pharmaceutical-approach-with-dr-dallen-mill-md-anesthesiologist.mp3 KLS Martin — https://www.klsmartin.com/en/   KLS Martin 35% Discount Code — StuckiFavs  Dr. Stucki's KLS Martin Instrument List & Instruction Video — https://www.klsmartin.com/dr-stucki-instruments Everyday Oral Surgery Website — https://www.everydayoralsurgery.com/ Everyday Oral Surgery on Instagram — https://www.instagram.com/everydayoralsurgery/ Everyday Oral Surgery on Facebook — https://www.facebook.com/EverydayOralSurgery/Dr. Grant Stucki Email — grantstucki@gmail.comDr. Grant Stucki Phone — 720-441-6059 

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-371 Overview: Beta-blockers have traditionally been used indefinitely after a myocardial infarction (MI), but this is now only recommended for a subset of patients. Listen in as faculty review new recommendations for managing patients with chronic cardiac disease, including how to determine which patients are good candidates for beta-blocker therapy and for how long. Episode resource links: Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2023 Sep 26;148(13):e148] [published correction appears in Circulation. 2023 Dec 5;148(23):e186]. Circulation. 2023;148(9):e9-e119.  Joo SJ. Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it. Acute Crit Care. 2023;38(3):251-260.  Guest: Alan M. Ehrlich, MD, FAAFP   Music Credit: Richard Onorato

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-371 Overview: Beta-blockers have traditionally been used indefinitely after a myocardial infarction (MI), but this is now only recommended for a subset of patients. Listen in as faculty review new recommendations for managing patients with chronic cardiac disease, including how to determine which patients are good candidates for beta-blocker therapy and for how long. Episode resource links: Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2023 Sep 26;148(13):e148] [published correction appears in Circulation. 2023 Dec 5;148(23):e186]. Circulation. 2023;148(9):e9-e119.  Joo SJ. Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it. Acute Crit Care. 2023;38(3):251-260.  Guest: Alan M. Ehrlich, MD, FAAFP   Music Credit: Richard Onorato

Welcome to the Happy Nurse Educator podcast by nursing.com. Since 2018, nursing.com has been at the forefront of nursing education, guiding over 400,000 nursing students to academic success while helping the average student raise their lowest grade by 11.6% with an impressive 99.25% NCLEX pass rate. Download free Lesson Plans at HappyNurseEducator.com Must Know NCLEX Meds Lesson Plan Objective By the end of the lesson, the nursing student will be able to identify and understand key medications commonly encountered on the NCLEX, focusing on Analgesics, Anticonvulsants, Anti-inflammatory/Steroids, Anticoagulants, Anti-Parkinsonian drugs, Beta Blockers, Potassium supplements, Respiratory drugs, Cardiac Glycosides, Antihypertensives, Psychotropic drugs, Maternity drugs, Antifungals, Anticholinergics, Oncology medications, Anti-Gout medications, and Ophthalmic medications (miotics and mydriatics). Through this lesson, nursing students will acquire knowledge about medication classes, indications, contraindications, and essential nursing considerations. The emphasis will be on recognizing potential side effects, monitoring for complications, and understanding the rationale behind medication administration. This foundational knowledge will empower students to approach NCLEX questions with confidence and ensure safe medication practices in clinical  settings. Download free Lesson Plans at HappyNurseEducator.com  

Show notes at pharmacyjoe.com/episode889. In this episode, I’ll discuss which beta-blockers should be dialyzed to treat toxicity. The post 889: Which beta-blockers should be dialyzed to treat toxicity? appeared first on Pharmacy Joe.

Show notes at pharmacyjoe.com/episode889. In this episode, I’ll discuss which beta-blockers should be dialyzed to treat toxicity. The post 889: Which beta-blockers should be dialyzed to treat toxicity? appeared first on Pharmacy Joe.

Three aspects of the recent AF guideline documents and a possible new treatment of POTS are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I AF Guidelines ACC/AHA Issue Updated Atrial Fibrillation Guideline https://www.medscape.com/viewarticle/998956 - Guideline doc: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001193 - CASTLE AF https://www.nejm.org/doi/full/10.1056/nejmoa1707855 - Analysis of US Inpatient Sample https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/1471-2261-14-73 - RAFT AF https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057095 - Beta Blockers in AF https://pubmed.ncbi.nlm.nih.gov/25193873/ Section 2 AF Guidelines – EARLY Rhythm Control Gets Emphasis - STOP AF https://www.nejm.org/doi/full/10.1056/NEJMoa2029554 - EARLY AF https://www.nejm.org/doi/full/10.1056/nejmoa2029980 - EAST https://www.nejm.org/doi/full/10.1056/NEJMoa2019422 - Natural History of AF https://www.jacc.org/doi/abs/10.1016/j.jacc.2019.09.050 Section 3 AF Guidelines – Dubious Upgrade of percutaneous LAAC - PROTECT and PREVAIL Meta-analysis 5-year https://doi.org/10.1016/j.jacc.2017.10.021 - PINNACLE FLX https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.050117 II. Postural Orthostatic tachycardia Syndrome Vagus Nerve Stimulation Promising In POTS https://www.medscape.com/viewarticle/998913 - Stavrakis et al. Noninvasive VNS for POTS https://doi.org/10.1016/j.jacep.2023.10.015 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Contributor: Dylan Luyten MD Educational Pearls: What is a Bradyarrhythmia? Also known as a bradyarrhythmia, it is an irregular heart rate that is also slow (below 60 beats per minute). What can cause it? Complete heart block AKA third-degree AV block; identified on ECG by a wide QRS, and complete dissociation between the atrial and ventricular rhythms with the ventricular being much slower. Treat with a pacemaker. Medication overdose, especially beta blockers. Many other drugs can slow the heart as well including: opioids, clonidine, digitalis, amiodarone, diltiazem, and verapamil to name a few. Electrolyte abnormalities, specifically hyperkalemia. Hypokalemia, hypocalcemia, and hypomagnesemia can also cause bradyarrhythmias. Myocardial infarction. Either by damaging the AV node or the conduction system itself or by triggering a process called Reperfusion Bradycardia. Hypothermia. Bradycardia is generally a sign of severe or advanced hypothermia. References Jurkovicová O, Cagán S. Reperfúzne arytmie [Reperfusion arrhythmias]. Bratisl Lek Listy. 1998 Mar-Apr;99(3-4):162-71. Slovak. PMID: 9919746. Simmons T, Blazar E. Synergistic Bradycardia from Beta Blockers, Hyperkalemia, and Renal Failure. J Emerg Med. 2019 Aug;57(2):e41-e44. doi: 10.1016/j.jemermed.2019.03.039. Epub 2019 May 30. PMID: 31155316. Wung SF. Bradyarrhythmias: Clinical Presentation, Diagnosis, and Management. Crit Care Nurs Clin North Am. 2016 Sep;28(3):297-308. doi: 10.1016/j.cnc.2016.04.003. Epub 2016 Jun 22. PMID: 27484658. Summarized by Jeffrey Olson MS2 | Edited by Meg Joyce & Jorge Chalit, OMSII  

Observational studies, another defense of digoxin, CTO-PCI, BP measurement, and a possible revolution in cardiovascular protection are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Observational Research Yeh; Credibility in Observational  Research https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064645 Hernan; Causal Language in Observational Research  https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2018.304337 Wang; RCT Duplicate Initiative https://jamanetwork.com/journals/jama/fullarticle/2804067 II. Defense of Digoxin Brophy; Beta Blockers, Digoxin, or Both https://doi.org/10.1016/j.cjca.2023.06.009 Dorian editorial https://doi.org/10.1016/j.cjca.2023.07.013 Ziff Digoxin Meta-analysis https://www.bmj.com/content/351/bmj.h4451.long DIG trial  https://www.nejm.org/doi/full/10.1056/nejm199702203360801 Davila Analysis of DIG Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801940/ Kotecha Meta-analysis of Beta Blockers https://pubmed.ncbi.nlm.nih.gov/25193873/ RATE-AF https://jamanetwork.com/journals/jama/fullarticle/2774407 III. CTO-PCI PCI of Chronic Total Occlusions Improves Angina, Quality of Life in Trials https://www.medscape.com/viewarticle/994739 JAMA Network Open Meta-analysis IV. BP Measurement One Size Doesn't Fit All in Blood Pressure Measurement https://www.medscape.com/viewarticle/995216 Ishigami Blood Pressure Measurement Comparison https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2807853 V. GLP-1 SELECT Trial Semaglutide Cuts Cardiovascular Events in Landmark Trial https://www.medscape.com/viewarticle/995270 SELECT Protocol Paper You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net